GlassScriptPhysician profile
Tri H Nguyen
NPI 1194942631
$4,366.18
in general payments reported to CMS, 2019-2025
28 companies · $739 in 2025
The $739 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $263 · 2020: $125 · 2021: $591 · 2022: $722 · 2023: $1,177 · 2024: $749 · 2025: $739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,495 · Education: $171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,494.54 |
| Education | $171.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $886.91 | 2019-2025 | |
| Janssen Biotech, INC. | $565.25 | 2020-2025 | Tremfya, Stelara, Simponi |
| Incyte Corporation | $459.33 | 2021-2025 | Opzelura |
| Amgen INC. | $328.97 | 2021-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $310.31 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $242.23 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $186.37 | 2021-2024 | Dupixent |
| Sun Pharmaceutical Industries INC. | $168.57 | 2022-2025 | Ilumya |
| Galderma Laboratories, L.P. | $162.59 | 2019-2025 | Aklief, Twyneo, Oracea |
| Leo Pharma INC. | $116.28 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.65 | 2023 | Spevigo |
| Dermavant Sciences, INC. | $101.07 | 2023-2024 | Vtama |
| Abbvie INC. | $96.42 | 2021-2022 | |
| Almirall LLC | $86.20 | 2021-2023 | Klisyri |
| Genzyme Corporation | $81.00 | 2019-2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $72.02 | 2022-2024 | Trintellix |
| Tactile Systems Technology INC | $57.04 | 2021-2025 | Nimbl, Flexitouch Plus |
| Genentech USA, INC. | $54.55 | 2020-2021 | |
| Celgene Corporation | $50.29 | 2019 | |
| Revance Therapeutics, INC. | $43.22 | 2024 | Daxxify |
| Arcutis Biotherapeutics, INC. | $43.02 | 2025 | Zoryve |
| Aclaris Therapeutics, INC. | $32.23 | 2019 | |
| Biofrontera INC. | $25.31 | 2019 | |
| Supernus Pharmaceuticals, INC. | $24.45 | 2019 | |
| Verrica Pharmaceuticals INC. | $16.40 | 2023 | Ycanth |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $16.24 | 2019 | |
| Pfizer INC. | $15.83 | 2023 | |
| Medtronic Vascular, INC. | $12.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tri Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.